U.S. markets open in 1 hour 7 minutes
  • S&P Futures

    4,406.25
    +22.25 (+0.51%)
     
  • Dow Futures

    34,320.00
    +191.00 (+0.56%)
     
  • Nasdaq Futures

    15,233.75
    +70.25 (+0.46%)
     
  • Russell 2000 Futures

    2,231.50
    +16.60 (+0.75%)
     
  • Crude Oil

    71.72
    -0.51 (-0.71%)
     
  • Gold

    1,773.90
    -4.90 (-0.28%)
     
  • Silver

    22.72
    -0.19 (-0.84%)
     
  • EUR/USD

    1.1721
    +0.0025 (+0.21%)
     
  • 10-Yr Bond

    1.3360
    0.0000 (0.00%)
     
  • Vix

    19.79
    -4.57 (-18.76%)
     
  • GBP/USD

    1.3708
    +0.0088 (+0.65%)
     
  • USD/JPY

    110.0290
    +0.2510 (+0.23%)
     
  • BTC-USD

    43,440.16
    +1,433.43 (+3.41%)
     
  • CMC Crypto 200

    1,088.99
    +48.51 (+4.66%)
     
  • FTSE 100

    7,073.75
    -9.62 (-0.14%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation.

  • The study will investigate the safety and optimal dose of NBTXR3 for non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back (recurrent).

  • The study has a two-cohort, open-label design consisting of two parts: (i) RT safety lead-in cohort (n=10) and NBTXR3 activated by RT dose-finding cohort (n=12); and (ii) expansion at the recommended Phase 2 dose with toxicity (n=12).

  • The dose levels to be explored are 22% and 33% of baseline gross tumor volume. The planned enrollment period is up to three years.

  • The Phase 1 trial is among five collaborator-led studies active and recruiting at The University of Texas MD Anderson Cancer Center. The third is to enroll its first patient.

  • NBTXR3 comprises functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.

  • Price Action: NBTX shares closed at $13.78 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.